Co-Founder & Chairman of the Board
Barry is a co-founder of AirXpanders, and is the Chairman of the Board. He was appointed to the Board in December 2006, and is a member of the Remuneration and Nomination Committee.
Barry brings more than 25 years of experience, primarily in the general management of medical device enterprises in the US. Currently, Barry is President and CEO of the medical device company PowerVision, Inc.
He is a three-time medical device company CEO, having taken one company public (RITA Medical) and sold another (NanoGram Devices) to its competitor (Wilson Greatbatch) one year into his tenure. RITA Medical developed and marketed a minimally invasive radio frequency ablation device used for cancer treatment. NanoGram Devices developed novel medical batteries based on a proprietary nanomaterials technology, with their first application directed at implantable defibrillators.
He holds degrees in Mechanical Engineering from MIT (BS) and Stanford (MS), as well as an MBA from Columbia Business School.
President, CEO & Executive Director
Scott has more than 25 years of executive management and leadership experience in the medical device industry with Boston Scientific, Orthofix Orthopedics, and BarrX Medical. Most recently, Scott was the President and CEO of Avantis Medical Systems, where he led the company through their Series C financing and two successful bridge financings. He oversaw the securing of Medicare reimbursement; the completion and publication of the largest tandem designed, randomized trial in medical device history; and the development of a next-generation imaging system for global, full-market release. Scott has a Bachelor of Science in Management from Indiana University in Bloomington, Indiana and has completed the Executive Management Program of both Columbia University and Babson College.
Co-Founder & Non-Executive Director
Teddy is a co-founder of AirXpanders, and was appointed to the Board in March 2005. He is a member of the Audit and Risk Committee.
Teddy is the Chief Executive Officer and sole shareholder of Shalon Ventures, an evergreen life science and technology incubator funded by the Shalon family. An accomplished entrepreneur, executive, and investor focusing on life science-oriented ventures, Teddy has more than 30 years of experience in medical device and medical product development in privately held companies such as Renew Medical, Airflow Medical, ThinOptics, Guard Medical, and Theracaine. He has founded and sold, in private transactions, several life sciences companies over the course of his career, including Osteogenix (sold to Medtronic), Synteni (sold to Incyte Pharmaceuticals), and Ivy Technologies (sold to Alcon).
Teddy holds an MS in Computer Science, BA in Physics, and a BS in Electrical Engineering from Washington University in St Louis, Missouri.
Dennis was appointed a Non-Executive Director in August 2012 and is a member of the Audit and Risk, and Remuneration and Nomination Committees.
Prior to selling the company to a Korean Pharma company in August 2016, Dennis was the CEO and President of Nuvesse Skin Therapies, a venture-backed cosmeceutical skincare company that has launched 12 products into the U.S. medical device market. He was previously the CEO and President of Merz Aesthetics, Inc. (from September 2011 to January 2013), after serving as President and Chief Business Officer from July 2007 and a board member from 2004 to 2007.
Dennis brings 30 years of experience in key executive roles in the plastic surgery market, including serving as the President of Mentor Aesthetics, one of the two largest global breast implant manufacturers.
Dennis currently is a member of two other boards in the aesthetic medical field, Nuvesse Skin Therapies and Suneva Medical.
Dennis has a BS in Biological Sciences from the University of California, Davis.
Gregory was appointed Non-Executive Director in April 2016, and is the chair of the Audit and Risk Committee.
Gregory most recently held the position of Executive Vice President, Operations and Chief Financial Officer at Accuray, a NASDAQ-listed radiation company that develops, manufactures and sells innovative tumor-treatment solutions. At Accuray, Gregory had responsibility over finance, treasury, investor relations, manufacturing, supply chain and facilities functions.
Gregory was previously a Director at Biolase, Inc., a U.S.-based, NASDAQ-listed medical device company that develops, manufactures, markets and sells laser systems and dental imaging equipment in dentistry. At Biolase, he held the position of Audit Committee Chair and Quality Committee Chair and was a member of the Compensation Committee.
Prior to this, Gregory was the Executive Vice President, Operations and Chief Financial Officer at Conceptus, Inc., a company which designs, develops, and markets minimally invasive devices for reproductive medical applications. During his time at Conceptus, its sales grew from US$8 million to US$141 million and adjusted EBITDA reached 20 percent of sales.
Gregory holds a BBA degree from the University of Michigan and an MBA degree from Michigan State University.
Zita was appointed Non-Executive Director in April 2016 and is Chairman of the Remuneration and Nomination Committee.
Zita’s most recent executive position was as the Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Frensenius Kabi, a provider of pharmaceutical products and medical devices to hospitals. She played a key role in the sustained development of the company in the Asia Pacific region, achieving double-digit growth and becoming the fastest growing region, contributing around 30% of total company revenue.
Previously, Zita was Vice President of Business Development at CSL Limited, a top 20 ASX biopharmaceutical company focused on developing and marketing protein therapeutics for serious unmet medical diseases.
In 2015, Zita joined the board of two early stage medical technology companies: 4Dx, a company involved in commercialising four-dimensional lung imaging technology; and Bionic Vision Technology, a developer of visual prostheses for patients with retinal degeneration conditions.
Zita currently serves as a Non-Executive Director of Starpharma Holdings, an ASX300 company and a leader in the development of dendrimer products for pharmaceutical, life science and other applications. She also serves on the board of the Vision Eye Institute, Australia’s leading provider of ophthalmic service
Zita holds a Bachelor of Science from the University of Melbourne, and is a graduate of the Australian Institute of Company Directors. She is a Fellow at the Australian Institute of Marketing, and a member of both Women on Boards and the Australian Institute of Company Directors.